Healthcare / BiotechnologyKOSDAQ
$2570.00
-35.00 (-1.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 13%
FCF escenarios
weak_data · normalized FCF $-1.4B · quality 35.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$42.8B
P/E
N/A
•EV/EBITDA
80.1x
↑ROE
-23.7%
↓Gross Margin
26.9%
↓Debt/Equity
2.16
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.1%
FCF CAGR
—
FCF margin
-2.4%
FCF / Net income
0.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $37.59B · net income $-5.55B · FCF $-889.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $37.59B | $37.59B | $43.20B | $38.62B | $46.92B |
| Net Income | $-5.55B | $-5.55B | $225.3M | $-5.05B | $-1.88B |
| EBITDA | $1.12B | $1.12B | $7.66B | $2.49B | $5.18B |
| EPS | -333.00 | -333.00 | -26.00 | -451.00 | -196.00 |
| Gross Margin | 26.9% | 26.9% | 29.4% | 16.3% | 14.3% |
| Operating Margin | -9.7% | -9.7% | 4.1% | -10.4% | -5.4% |
| Net Margin | -14.8% | -14.8% | 0.5% | -13.1% | -4.0% |
| Balance Sheet | |||||
| Debt/Equity | 2.16 | 2.16 | 1.74 | 2.38 | 1.37 |
| Current Ratio | 0.81 | 0.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-889.8M | $-889.8M | $-1.44B | $-4.11B | $-9.01B |
| Returns | |||||
| ROE | -23.7% | -23.7% | 0.8% | -23.0% | -6.3% |
| Valuation | |||||
| EV/EBITDA | 80.09 | 80.09 | 9.71 | 28.52 | 14.41 |
| P/B | 1.83 | 1.83 | 0.93 | 1.10 | 1.26 |
| Growth & Yield | |||||
| Revenue Growth | -13.0% | -13.0% | 11.9% | -17.7% | — |
| EPS Growth | -1180.8% | -1180.8% | 94.2% | -130.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+65.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-26.00 → -333.00
Residual
+65.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.